Comparative Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Advanced Cancer: A Systematic Review and Meta-Analysis.
advanced cancer
combination immunotherapy
efficacy
ipilimumab
nivolumab
safety
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2020
2020
Historique:
received:
06
09
2019
accepted:
14
01
2020
entrez:
3
3
2020
pubmed:
3
3
2020
medline:
3
3
2020
Statut:
epublish
Résumé
Combination therapy with immune checkpoint inhibitors (ICIs) has been applied in the clinic to achieve synergistic effects and to improve clinical efficacy. Compared with monotherapy, combination therapy has promising efficacy against various advanced cancers. To further verify the effectiveness of combination therapy, we conducted a meta-analysis of the efficacy and safety of nivolumab (NIVO) and NIVO plus ipilimumab (IPI) in advanced cancer. Electronic databases (PubMed, EMbase, and The Cochrane Library) were systematically searched for applicable studies published in English between January 1990 and June 2019. Relevant outcomes included objective response rate (ORR), disease control rate (DCR), median progression-free survival (mPFS), median overall survival (mOS), and grade 3-4 adverse events (AEs). A total of 1,297 patients from six studies were included. Compared with NIVO alone, NIVO + IPI was more efficacious for advanced tumors. Pooled outcome values were: ORR, 1.73 (95% CI: 1.34-2.23); DCR, 1.80 (95% CI: 1.21-2.69); mPFS, 0.22 (95% CI: 0.03-0.41); mOS, 0.03 (95% CI: -0.20-0.26); and grade 3-4 AEs, 3.64 (95% CI: 2.86-4.62). NIVO + IPI is more effective than NIVO alone for the treatment of advanced cancer and can significantly improve ORR and DCR and prolong mPFS. Due to the limited quality and quantity of the included studies, more high-quality studies are needed to validate the above conclusions.
Sections du résumé
BACKGROUND
BACKGROUND
Combination therapy with immune checkpoint inhibitors (ICIs) has been applied in the clinic to achieve synergistic effects and to improve clinical efficacy. Compared with monotherapy, combination therapy has promising efficacy against various advanced cancers. To further verify the effectiveness of combination therapy, we conducted a meta-analysis of the efficacy and safety of nivolumab (NIVO) and NIVO plus ipilimumab (IPI) in advanced cancer.
METHODS
METHODS
Electronic databases (PubMed, EMbase, and The Cochrane Library) were systematically searched for applicable studies published in English between January 1990 and June 2019. Relevant outcomes included objective response rate (ORR), disease control rate (DCR), median progression-free survival (mPFS), median overall survival (mOS), and grade 3-4 adverse events (AEs).
RESULTS
RESULTS
A total of 1,297 patients from six studies were included. Compared with NIVO alone, NIVO + IPI was more efficacious for advanced tumors. Pooled outcome values were: ORR, 1.73 (95% CI: 1.34-2.23); DCR, 1.80 (95% CI: 1.21-2.69); mPFS, 0.22 (95% CI: 0.03-0.41); mOS, 0.03 (95% CI: -0.20-0.26); and grade 3-4 AEs, 3.64 (95% CI: 2.86-4.62).
CONCLUSION
CONCLUSIONS
NIVO + IPI is more effective than NIVO alone for the treatment of advanced cancer and can significantly improve ORR and DCR and prolong mPFS. Due to the limited quality and quantity of the included studies, more high-quality studies are needed to validate the above conclusions.
Identifiants
pubmed: 32116716
doi: 10.3389/fphar.2020.00040
pmc: PMC7033417
doi:
Types de publication
Systematic Review
Langues
eng
Pagination
40Informations de copyright
Copyright © 2020 Yang, Jin, Pang, Huang, Wang, Zhang, Tuo, Wu, Wang and Zhu.
Références
MAbs. 2019 Aug/Sep;11(6):1139-1148
pubmed: 31242068
Cancer Immunol Res. 2018 Sep;6(9):1069-1081
pubmed: 30018045
Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):344-351
pubmed: 28463153
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Lancet Oncol. 2018 Mar;19(3):416-426
pubmed: 29370992
Neuro Oncol. 2018 Apr 9;20(5):674-686
pubmed: 29106665
Am Health Drug Benefits. 2015 Mar;8(Spec Feature):180-3
pubmed: 26629287
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Lancet Oncol. 2019 Feb;20(2):239-253
pubmed: 30660609
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
Cancer Res. 2013 Jun 15;73(12):3591-603
pubmed: 23633484
J Urol. 2012 Dec;188(6):2148-9
pubmed: 23141220
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
Medicine (Baltimore). 2017 Jun;96(26):e7325
pubmed: 28658143
Cancer Cell. 2015 Apr 13;27(4):439-49
pubmed: 25858803
Ann Oncol. 2018 Apr 1;29(4):959-965
pubmed: 29408986
J Immunother Cancer. 2018 Jan 23;6(1):8
pubmed: 29357948
Immunol Rev. 2008 Aug;224:166-82
pubmed: 18759926
Eur J Cancer. 2018 Dec;105:114-126
pubmed: 30447539
Lancet Oncol. 2019 Feb;20(2):297-310
pubmed: 30658932
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4275-80
pubmed: 20160101
Cancer Res. 2015 Sep 15;75(18):3800-11
pubmed: 26208901
J Clin Oncol. 2018 Oct 1;36(28):2836-2844
pubmed: 30110194
Adv Exp Med Biol. 2016;890:149-74
pubmed: 26703804
Crit Rev Oncol Hematol. 2019 Jun;138:178-189
pubmed: 31092375
Lancet Oncol. 2016 Nov;17(11):1558-1568
pubmed: 27622997
Eur J Cancer. 2019 Jul;116:137-147
pubmed: 31195357
Lancet Respir Med. 2019 Mar;7(3):260-270
pubmed: 30660511
Cancer Discov. 2017 Mar;7(3):264-276
pubmed: 28031159
Lancet Oncol. 2019 Jul;20(7):948-960
pubmed: 31160251
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
Ann Oncol. 2017 Jul 1;28(7):1484-1494
pubmed: 28383639
Cancer Treat Rev. 2015 Dec;41(10):868-76
pubmed: 26589760
J Clin Oncol. 2019 Jul 1;37(19):1608-1616
pubmed: 31100038
Nat Commun. 2016 Aug 08;7:12335
pubmed: 27498556
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Sci Transl Med. 2015 Apr 22;7(284):284ra56
pubmed: 25904740
Clin Cancer Res. 2011 Nov 15;17(22):6958-62
pubmed: 21900389
Drug Discov Today. 2017 Aug;22(8):1266-1273
pubmed: 28600190
Lancet Oncol. 2018 May;19(5):672-681
pubmed: 29602646
Lancet Oncol. 2018 Nov;19(11):1480-1492
pubmed: 30361170
Ann Oncol. 2018 Jan 1;29(1):71-83
pubmed: 29069302
Nat Rev Immunol. 2018 Mar;18(3):153-167
pubmed: 28990585
BMC Med Res Methodol. 2008 Apr 21;8:22
pubmed: 18426565
N Engl J Med. 2015 Jan 22;372(4):311-9
pubmed: 25482239
Int J Cancer. 2016 Jun 1;138(11):2549-61
pubmed: 26537995